Infliximab is a chimeric monoclonal antibody that binds specifically to human tumor necrosis factor-alpha (TNF-α), decreasing the effect of the cytokine in inflammatory diseases.
Objective:
The aim of this study was to review the efficacy and safety of infliximab in the treatment of dermatological diseases.
Methods:
A MEDLINE search (1966–January 2003), using the keyword “infliximab” was performed to find relevant articles pertaining to the use of infliximab in dermatology.
Results:
Infliximab has been used in the following dermatological diseases: psoriasis, Behçet's disease, graft versus host disease, hidradenitis suppurativa, panniculitis, pyoderma gangrenosum, SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome, sarcoidosis, subcorneal pustular dermatosis, Sweet's syndrome, toxic epidermal necrolysis, and Wegener's granulomatosis. There is a generally good safety profile for infliximab, which is similar to that when it is used to treat Crohn's disease and rheumatoid arthritis.
Conclusion:
Although not approved for use in dermatological diseases, there have been numerous reports of the efficacy of infliximab in cutaneous inflammatory diseases. The most promise lies in those diseases that have increased amounts of TNF-α in the cutaneous lesions, such as psoriasis.
Get full access to this article
View all access options for this article.
References
1.
KristensenMChuCQEedyDJ. Localization of tumor necrosis factor-alpha (TNF-α) and its receptors in normal and psoriatic skin: Epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol1993; 94:354–362.
2.
ScallonBCaiASolowskiN. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther2002; 301:418–426.
3.
KeaneJGershonSWiseRP. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med2001; 345:1098–1104.
4.
LaDucaJRGaspariAA. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseaseDermatol Clin2001; 19:617–635.
5.
SugermannPBSavageNWSeymourGJ. Is there a role for tumor necrosis factor-alpha (TNF-alpha) in oral lichen planus?J Oral Pathol Med1996; 25:219–224.
6.
WakefieldPEJamesWDSamlaskaCP. Tumor necrosis factor. J Am Acad Dermatol1991; 24:675–685.
7.
Tillie-LeblondIGossetPJaninA. Tumor necrosis factor-α release during systemic reaction in cold urticaria. J Allergy Clin Immunol1994; 93:501–509.
SmithMRMungerWEKungH-F. Direct evidence for an intracellular role for tumor necrosis factor-α. J Immunol1990; 144:162–169.
10.
BeutlerBA, The tumor necrosis factors: Cachectin and lymphotoxin. Hosp Pract (off ED)1990; Feb 15:45–56 in [ref 6].
11.
BeutlerBAMilsarkIWCeramiA. Cachectin/tumor necrosis factor: Production, distribution, and metabolic fate in vivoJ Immunol1985; 135:3972–3977.
12.
TanakaNFujiokaATajimaS. Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: Interleukin-1 beta and tumour necrosis factor-alpha stimulate its secretion in vitro. Br J Dermatol2000; 143:728–732.
13.
GrovesRWAllenMHRossEL. Tumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br J Dermatol1995; 132:345–352.
MorettiSSpallanzaniAAmatoL. Vitiligo and epidermal microenvironment: Possible involvement of keratinocyte-derived cytokines. Arch Dermatol2002; 138:273–274.
16.
PiguetPFGrauGEVassalliP. Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosisAm J Pathol1990;136:103–110.
17.
ArendWP. Mode of action of cytokine inhibitorsJ Rheumatol2002; 29:16–21.
KobbeGSchneiderPRohrU. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant2001; 28:47–49.
20.
EstrachCMpofuSMootsRJ. Behçet's syndrome: Response to infliximab after failure to etanerceptRheumatology2002; 41: 1213–1214.
21.
GottliebABMasudSRamamurthiR. Pharmacodynamic and pharmacokinetic response anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol2003; 48:68–75.
22.
WilliamsJDLGriffithsCEM. Cytokine blocking agents in dermatologyClin Exp Dermatol2002; 27:585–590.
23.
TutuncuZMorganGJKavanaughA. Anti-TNF therapy for other inflammatory conditionsClin Exp Dermatol2002; 20:S146–S151.
24.
FarrellRJShahSALodhaviaPJ. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol2000; 95:3490–3497.
25.
SfikakisPPTheodossiadisPGKatsiariCG. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet2002; 358:295–296.
26.
RobertsonLPHicklingP. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximabRheumatology2002; 40:473–474.
27.
GülA. Behçet's disease: An update on the pathogenesisClin Exp Dermatol2001; 19:S6–S12.
28.
SayinalpNÖzcebeOlÖzdemirO. Cytokines in Behçet's disease. J Rheumatol1996; 23:321–323.
29.
SfikakisPP. Behçet's disease: A new target for anti-tumour necrosis factor treatmentAnn Rheum Dis2002; 61:ii51–ii53.
30.
GoossensPHVerburgRJBreedveldFQ. Remission of Behçet's syndrome with tumour necrosis factor α blocking therapyAnn Rheum Dis2002; 60:637.
31.
RozenbaumMRosnerIPortnoyE. Remission of Behçet's syndrome with TNF[alpha] blocking treatmentAnn Rheum Dis2002; 61:283–284.
32.
AlecuMGeleriuLComanG. The interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor alpha serological levels in localized and systemic sclerosis. Rom J Intern Med1998; 36:251–259.
33.
HughesAPJacksonJMCallenJP. Clinical features and treatment of peristomal pyoderma gangrenosumJAMA2000; 284:1546–1548.
34.
HervéPFleschMTiberghienP. Phase I–II trial of a monoclonal anti-tumor necrosis factor α antibody for the treatment of refractory severe acute graft-versus-host disease. Blood1992; 79:3362–3368.
35.
BohESherrodJSafahH. Successful use of infliximab in a patient with graft versus host disease [poster]. World Congress of Dermatology, Paris, France, July 1–5, 2002.
36.
AltunayIKGokdemirGKurtA. Hidradenitis suppurativa and squamous cell carcinoma. Dermatol Surg2002; 28:88–90.
37.
DaoudMSDickenCH, Apocrine Glands. In: FreedbergIMEisenAZWolffK, eds. Fitzpatrick's Dermatology in General Medicine. 5New York: McGraw-Hill, 1999.
Von derWerthJMJemecGBE. Morbidity in patients with hidradenitis suppurativaBr J Dermatol2001; 144:809–813.
40.
MartínezFNosPBenllochS. Hidradenitis suppurativa and Crohn's disease: Response to treatment with infliximab. Inflamm Bowel Dis2001; 7:323–326.
41.
KatsanosKHChristodoulouDKTsianosEV. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patientAm J Gastroenterol2002; 97:2155–2156.
42.
SullivanTPWelshEKerdelFA. Infliximab for hidradenitis suppurativa [poster]. World Congress of Dermatology, Paris, France July 1–5, 2002.
43.
HumeniukJMGliptisEG. Infliximab in the treatment of panniculitis. World Congress of Dermatology, Paris, France, July 1–5, 2002.
44.
YuHSChangKLYuCL. Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol1997; 108:527–529.
45.
LöntzWSirsjöALiuM. Increased mRNA expression of maganese superoxide dismutase in psoriasis skin lesions and in cultured human keratinocytes exposed to IL-Iβ and TNF-α. Free Radic Biol Med1995; 18:349–355.
46.
NickoloffBJKarabinGDBarkerJNWN. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol1991; 138:129–140.
KirbyBMarslandAMCarmichaelAJ. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol2001; 26:27–29.
49.
PowellFCO'KaneM. Management of pyoderma gangrenosumDermatol Clin2002; 20:347–355viii.
50.
NussbaumRKruegerJG, Treatment of inflammatory dermatoses with novel biologic agents: A primer. In: JamesWDCockerellCJMaloneyME, eds Advances in Dermatology. 18St. Louis: CV: Mosby, 2002.
51.
WeinbergJMSainiR. Biologic therapy for psoriasis: The tumor necrosis factor inhibitors-infliximab and etanerceptCutis2003; 71:25–29.
52.
MeasePJ. Tumour necrosis factor (TNF) in psoriatic arthritis: Pathophysiology and treatment with TNF inhibitorsAnn Rheum Dis2002; 61:298–304.
53.
JacksonCG. Immunomodulating drugs in the management of psoriatic arthritisAm J Clin Dermatol2001; 2:367–375.
54.
ZabranieckiLFourniéB. TNFα inhibition in psoriatic arthritis: Cause for hopeJoint Bone Spine2001; 68:106–108.
55.
GottliebABRomanoPChaudhariU. Infliximab prevents relapse of moderate to severe psoriasis in responding patients [poster]. World Congress of Dermatology, Paris, France, July 1–5, 2002.
56.
OhCJDasKMGottliebAB. Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesionsJ Am Acad Dermatol2000; 42:829–830.
57.
SchopfREAustHKnopJ. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α, infliximabJ Am Acad Dermatol2002; 46:886–891.
58.
ChaudhariURomanoPMulcahyLD. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomized trial. Lancet2001; 357:1842–1847.
59.
CauzaESpakMCauzaK. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int2002; 22:227–232.
60.
MangRStegeHRuzickaT. Response of severe psoriasis to infliximab. Dermatology2002; 204:156–157.
61.
OgilvieALJAntoniCDechantC. Treatment of psoriatic arthritis with antitumor necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol2001; 144:587–589.
62.
NewlandMRWeinsteinAKerdelF. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch typeInt J Dermatol2002; 41:449–452.
63.
TanMHGordonMLebwohlO. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol2001; 137:930–933.
64.
GrangeFGjilali-BouzinaFWeissAM. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: Rapid cure with infliximab. Dermatology2002; 205:278–280.
65.
WolffKStinglG, Pyoderma gangrenosum. In: FreedbergIMEisenAZWolffK, eds Fitzpatrick's Dermatology in General Medicine. 5New York: McGraw-Hill, 1999.
TriantafillidisJKCheracakisPSklavainaM. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol2002; 37:863–865.
68.
LímováMBolceR. Management of pyoderma gangrenosum with infliximab (Remicade) [poster]. World Congress of DermatologyParis, France, July 1–5, 2002.
69.
SheldonDGSawchukLLKozarekRA. Twenty cases of peristomal pyoderma gangrenosum: Diagnostic implications and management. Arch Surg2000; 135:564–568.
70.
BatresLAMamulaPBaldassanoRN. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn diseaseJ Pediatr Gastroenterol Nutr2002; 34:558–560.
71.
WagnerADAndresenJJendroMC. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum2002; 46:1965–1968.
72.
KarolyiZHarhaiIErosN. [Dermatologic aspects of SAPHO-syndrome]Orv Hetil2001; 142:1801–1804.
73.
OlivieriIPadulaACiancioG. Successful treatment of SAPHO syndrome with infliximab: Report of two cases. Ann Rheum Dis2002; 61:375–376.
74.
SharmaOP, Sarcoidosis of the skin. In: FreedbergEVIEisenAZWolffK, eds Fitzpatrick's Dermatology in General Medicine. 5New York: McGraw-Hill, 1999.
75.
CookMC. Infliximab therapy for complicated sarcoidosisAnn Intern Med2002; 137:296.
76.
PettersonJAZochodneDWBellRB. Refractory neurosarcoidosis responding to infliximab. Neurology2002; 59:1660–1661.
77.
BaughmanRPLowerEE. Infliximab for refractory sarcoidosisSarcoidosis Vase Diffuse Lung Dis2001; 18:70–74.
78.
YeeAMFPochapinMB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-α therapyAnn Intern Med2001; 135:27–31.
79.
DelaporteEColombelJFNguyen-MailferC. Subcorneal pustular dermatosis in a patient with Crohn's disease. Acta Derm Venereol1992; 72:301–302.
80.
GrobJJMegeJLCapoC. Role of tumor necrosis factor-alpha in Sneddon–Wilkinson subcorneal pustular dermatosis. A model of neutrophil priming in vivo. J Am Acad Dermatol1991; 25:944–947.
81.
CorreiaODelgadoLBarbosaIL. Increased interleukin 10, tumor necrosis factor α, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol2002; 47:58–62.
82.
PaquetPPaquetFAl SalehW. Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol2000; 22:413–417.
83.
FritschPORuiz-MaldonadoR, Stevens–Johnson syndrome—toxic epidermal necrolysis. In: FreedbergIMEisenAZWolffK, eds Fitzpatrick's Dermatology in General Medicine. 5New York: McGraw-Hill, 1999.
RedondoPDe FelipeIDe la PenaA. Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis: Treatment with N-acetylcysteineBr J Dermatol1997; 136:645–646.
86.
GhislainPRoujeauJ. Treatment of severe drug reactions: Stevens–Johnson Syndrome, Toxic Epidermal Necrolysis and Hypersensitivity SyndromeDermatol Online J2002; 8:5.
87.
FischerMFiedlerEMarschWC. Antitumour necrosis factor-α antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol2002; 146:707–708.
88.
BartolucciPRamanoelinaJCohenP. Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides: An open pilot study on 10 patients. Rheumatology2002; 41:1126–1132.
89.
MandellBFHoffmanGS, Systemic necrotizing arteritis. In: FreedbergIMEisenAZWolffK, eds Fitzpatrick's Dermatology in General Medicine. 5New York: McGraw–Hill, 1999.
90.
LamprechtPVoswinkelJLilienthalT. Effectiveness of TNF-α blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology2002; 41:1303–1307.
91.
LamprechtPArbachOVoswinkelJ. Induction of remission with infliximab in therapy-refractory Wegener's granulomatosis—Follow-up of six patients. Dtsch Med Wochenschr2002; 127:1876–1880.
92.
HengMCYKhooMCoopermanA. Haemorrhagic cellulitis: A syndrome associated with tumor necrosis factor-α. Br J Dermatol1994; 130:65–74.
93.
ZalewskaABrzezinska-BlaszczykEOmuleckiA. Functional studies of skin mast cells in lichen planus. Arch Dermatol Res1997; 289:261–264.
94.
Simark-MattssonCBergenholtzGJontellM. Distribution of interleukin-2, -4, -10, tumour necrosis factor-alpha and transforming growth factor-beta mRNAs in oral lichen planus. Arch Oral Biol1999; 44:499–507.
95.
SimonMJrGruschwitzMS. In situ expression and serum levels of tumour necrosis factor alpha receptors in patients with lichen planusActa Derm Venereol1997; 77:191–193.
96.
SklavounouAChrysomaliEScorilasA. TNF-alpha expression and apoptosis-regulating proteins in oral lichen planus: A comparative immunohistochemical evaluation. J Oral Pathol Med2000; 29:370–375.
97.
FelicianiCTotoPAmerioP. In vitro C3 mRNA expression in pemphigus vulgaris: Complement activation is increased by IL1α and TNF-α. J Cut Med Surg1999; 3:140–144.
98.
López-RoblesEAvalos-DíazEVega-MemijeE. TNFα and IL-6 are mediators in the blistering process of pemphigus. Int J Dermatol2001; 40:185–188.
99.
FelicianiCTotoPAmerioP. In vitro and in vivo expression of interleukin-lα and tumor necrosis factor-α in pemphigus vulgaris: Interleukin-lα and tumor necrosis factor-α are involved in acantholysis. J Invest Dermatol2000; 114:71–77.
100.
AmeglioFD'AuriaLCordiali-FeiP. Bullous pemphigoid and pemphigus vulgaris: Correlated behavior of serum VEGF, E-selectin and TNF-alpha levels. J Biol Regul Homeost Agents1997; 11:148–153.
StanleyJR, Pemphigus. In: FreedbergIMEisenAZWolffK, eds Fitzpatrick's Dermatology in General Medicine. 5New York: McGraw–Hill, 1999.
103.
StanleyJR, Bullous pemphigoid. In: FreedbergIMEisenAZWolffK, eds Fitzpatrick's Dermatology in General Medicine. 5New York: McGraw–Hill, 1999.
104.
UmeharaHKumagaiSMurakamiM. Enhanced production of interleukin-1 and tumor necrosis factor alpha by cultured peripheral blood monocytes from patients with scleroderma. Arthritis Rheum1990; 33:893–897.
105.
NeedlemanBWWigleyFMStairRW. Interleukin-l, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with sclerodermaArthritis Rheum1992; 35:67–72.
106.
BellaS DeliaMolteniMMascagniB. Cytokine production in scleroderma patients: Effects of therapy with either iloprost or nifedipine. Clin Exp Rheum1997; 15:135–141.
107.
HermesBProchazkeAKHaasN. Upregulation of TNF-α and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol1999; 103:307–314.
108.
FrezzoliniADe PitàOCassanoN. Evaluation of inflammatory parameters in physical urticarias and effects of an anti-inflammatory/antiallergic treatment. Int J Dermatol2002; 41:431–438.
109.
BarlowRJRossELMacdonaldD. Adhesion molecule expression and the inflammatory cell infiltrate in delayed pressure urticaria. Br J Dermatol1994; 131:341–347.
110.
BresslerRB. Pathophysiology of chronic urticariaImmunol Allergy Clin North Am1995; 15:659–677.
111.
KanoYOriharaMShioharaT. Cellular and molecular dynamics in exercise-induced urticarial vasculitis lesionsArch Dermatol1998; 134:62–67.
112.
HanauerSB, Review article: Safety of Infliximab in clincal trialsAliment Pharmacol Ther1999; 13:16–22.
113.
CohenRDTsangJFHanauerSB. Infliximab in Crohn's disease: First anniversary clinical experienceAm J Gastroenterol2000;95:3469–3477.
114.
Centocor. Adverse events in patients treated with Remicade2002 (data on file).
115.
SoykanIErtanCOzdenA. Severe anaphylactic reaction to infliximab: Report of a caseAm J Gastroenterol2000; 95:2395–2396.
116.
CharlesPJSmeenkRJTDe JongJ. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α. Arthritis Rheum. 2002; 43:2383–2390.
CrandallWVMacknerLM. Infusion reactions to infliximab in children and adolescents: Frequency, outcome and a predictive modelAliment Pharmacol Ther2003; 17:75–84.
124.
StephensMCShepanskiMAMamulaP. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol2003; 98:104–111.
125.
StevensMPLeeWWMakarowskiWS. Infliximab in the treatment of psoriatic arthritis and psoriasis2002.
126.
O'QuinnRPMillerJL. The effectiveness of tumor necrosis factor α antibody (infliximab) in treating recalcitrant psoriasisArch Dermatol2002; 138:644–648.
127.
ElewskiBE. Infliximab for the treatment of severe pustular psoriasisJ Am Acad Dermatol2002; 47:796–797.
